David Arthur, Salarius CEO

FDA lifts par­tial hold on Salarius' Ew­ing sar­co­ma drug tri­al

Hous­ton biotech Salarius Phar­ma­ceu­ti­cals has re­ceived some pos­i­tive news from the FDA.

Salarius an­nounced Tues­day that the agency re­moved a par­tial clin­i­cal hold from its …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.